select trial glp 1 semaglutide results Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design SELECT Cardiovascular Trial Information Mapping the effectiveness and risks

The randomized, double-blind study demonstrated statistically significant improvements in blood sugar control at all tested doses, along with meaningful weight loss outcomes at the 14 mg dose compared to the placebo group. High-dose oral semaglutide has since demonstrated more substantial results

Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes

AI is also improving clinicians ability to understand patients metabolic health beyond standard measures like blood glucose and A1C

Setting up your account for Sign to affirm:

Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options

A phase 3, double-blind, randomized, placebo-controlled trial was conducted across seven countries